Identification of a predictive gene signature to recMAGE A3 antigen-specific cancer immunotherapy in metastatic melanoma and non-small-cell lung cancer
Purpose: To evaluate the presence of a gene expression signature present before treatment as predictive of response to treatment with MAGE‑A3 immunotherapeutic in metastatic melanoma patients and to validate its predictivity in adjuvant therapy of early-stage lung cancer.
Cancer Type: Melanoma
GPL: 570
Number of Genes with Data: 978
Number Observations: 65
Number Outputs: 1
Imbalanced Ratio: 0.264705882
Default Task: Classification